Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tinoridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tinoridine SCHEMBL24761 | 0.99 | ADORA1 (1.00) | ADORA1LMNAMEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL10855850 | 0.93 | ADORA1 (0.84) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL14234268 | 0.91 | ADORA1 (0.84) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL6993570 | 0.91 | ADORA1 (0.84) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL7719502 | 0.90 | ADORA1 (0.83) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL6992518 | 0.89 | ADORA1 (0.81) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL6993515 | 0.89 | GAA (1.00) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL16007300 | 0.88 | ADORA1 (0.80) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL7719431 | 0.87 | GAA (0.89) | ADORA1LMNAMEN1MAPTKMT2A | |
| SCHEMBL7089989 | 0.86 | GAA (0.87) | ADORA1LMNAMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025081123-A1 | METHODS AND COMPOSITIONS FOR IMPROVING T CELL IMMUNOTHERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025032112-A1 | METHODS FOR THE TREATMENT OF TYPE 2-MEDIATED DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-02-13 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-4879274-A | IMPROVED ABSORPTION | KAO CORPORATION (JP) | 1989-11-07 | — | — | US | claimed |
| US-4016276-A | Treatment of liver dysfunction with 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine hydrochloride | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1977-04-05 | — | — | US | claimed |
| JP-2188521-A | — | — | None | — | — | JP | disclosed |
| JP-61129126-A | — | — | None | — | — | JP | disclosed |
| EP-4739297-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739299-A1 | MODELS OF CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739298-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739300-A1 | MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-0227836-A1 | SUSTAINED RELEASING PATCH | TEIJIN LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0216303-A2 | External medication | Kao Corporation (JP) | 1987-04-01 | — | — | EP | disclosed |
| JP-S61129126-A | ANTITUMOR AGENT | KUREHA CHEM IND CO LTD | 1986-06-17 | — | — | JP | disclosed |
| US-4016276-A | Treatment of liver dysfunction with 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine hydrochloride | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1977-04-05 | — | — | US | disclosed |
| US-4016276-A | Treatment of liver dysfunction with 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine hydrochloride | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1977-04-05 | — | — | US | disclosed |
| US-4016276-A | Treatment of liver dysfunction with 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine hydrochloride | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1977-04-05 | — | — | US | disclosed |